The repercussions of Pfizer's dramatic Exubera exit are finally
filtering through to West Pharmaceutical Services, with the
company preparing to restructure its affected Tech Group
contract manufacturing unit.
Eli Lilly is remaining optimistic about its yet-to-be-approved
inhaled insulin despite the dramatic downfall of Pfizer's Exubera.
But is Exubera's fall from grace an indication of things to come
for inhaled diabetes treatments?
With yesterday's perhaps unsurprising news that Pfizer has cut its
losses and pulled out of the inhaled insulin market by dropping
Exubera and giving up on second generation devices, the world's
biggest pharma firm is in...
Pfizer revealed today that it is abandoning its once-touted
blockbuster Exubera, ending months of speculation as to whether the
fledging world-first inhalable insulin would sink or swim in the
fierce waters of pharma.
An improved inhalable insulin product developed by collaborating UK
and US firms has just completed a glucose clamp study in the US,
with results suggesting that the product could pose a significant
threat to Pfizer's Exubera...
Bespak, one of the two contract manufacturers of Pfizer's inhaled
insulin Exubera, has announced it will cut a "significant" number
of jobs as sales of the once-touted blockbuster are falling short
Eager to find a formulation that will give Pfizer's inhalation
device Exubera (insulin rDNA) a run for its money, Nastech is
initiating a Phase I study to compare Exubera to its insulin nasal
spray and to an approved injectable...
Innovata is moving forward with its dry powder pulmonary insulin
inhaler, which it claims has a formulation superior to Exubera,
gearing up for Phase II clinical trials and anticipating a new
partnership deal by the end of the year.
Bespak is now ramping up manufacturing of Chiesi Farmaceutici's new
dry powder inhaler (DPI), in preparation for clinical trials of the
device in patients with asthma and COPD (chronic obstructive